X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

With Biologics Spread Catalent Buys NJ Cell Therapy Plant

Content Team by Content Team
28th April 2022
in News
Catalent To Open New Clinical Supply Facility In San Diego

Catalent, the high-flying CDMO, is buying a cell therapy unit on the East Coast, only days after spending $350 million to strengthen up biologics production in Indiana.

Catalent announced on April 25th that it had paid $44.5 million for Erytech Pharma’s commercial cell treatment plant in Princeton, New Jersey. Catalent will contribute to the long-term supply of Erytech’s principal product candidate, eryaspase (also known as Graspa), which is being developed for acute lymphoblastic leukaemia. According to the company, all employees from the Erytech facility will join the Catalent team.

As per Catalent, the 30,900-square-foot facility includes 16 production suites as well as labs for analytical, quality control, and microbial testing. Catalent intends to turn the facility into a “strategic campus” where it will develop and manufacture cell therapies on a clinical and commercial scale. The Princeton site is conveniently located near Catalent’s Baltimore facilities, where the company develops as well as manufactures viral vectors and plasmid DNA, which are critical components in many cell and gene therapies.

According to Catalent, the site will function in combination with the company’s clinical-scale cell therapy unit in Houston.

Catalent has also secured a lease for a 23,000-square-foot facility adjacent to the plant that might be used for additional lab or production space. It’s also scooped up another structure in University Square Campus Park in Princeton for future development.

Catalent will assist Erytech in the development of its pipeline of encapsulated red-blood-cell-based medicines, which it is exploring against serious forms of cancer and orphan disorders, in addition to Erytech’s red blood cell candidate Graspa, the firms said.

Catalent’s professional and qualified staff are already employed at the facility, and the skills it has in place and the ability to rapidly add additional space on the same site allow it to grow significantly, creating a U.S. campus and centre of excellence for cell therapy design and manufacturing that will serve customers around the world, said President of Catalent cell and gene therapy, Manja Boerman, Ph.D.

Catalent has six cell and gene therapy facilities, including locations in Maryland and Texas, as well as Belgium and Germany. According to the CDMO, the facilities range from small-to large-scale clinical and commercial production through fill and finish.

The factory purchase comes on the heels of Catalent’s decision to expand its manufacturing operations in the United States. Last week, the company announced plans to invest $350 million in its Bloomington, Indiana facility to improve biologics operations and create more than 1,000 jobs.

Catalent has also acquired a biologics design and manufacturing centre near Oxford, UK, and in mid-March completed a $30 million upgrade at its Limoges, France, facility.

Previous Post

Cancer Risk Leads Pfizer Recall Blood Pressure Drug From US

Next Post

Rinvoq From Abbvie Gets Fourth FDA Approval In Five Months

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post
Conver to wp

Rinvoq From Abbvie Gets Fourth FDA Approval In Five Months

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In